CN Patent

CN1905871A — N－羟基－4－{5－[4－(5－异丙基－2－甲基－1,3－噻唑－4－基)苯氧基]戊氧基}苄脒2甲磺酸盐

Assigned to Dong Wha PharmInd Co ltd · Expires 2007-01-31 · 19y expired

What this patent protects

公开了N－羟基－4－{5－[4－(5－异丙基－2－甲基－1，3－噻唑－4－基)苯氧基]戊氧基}苄脒2甲磺酸盐，其具有优异的生物利用率。也公开了制备所述化合物的方法和包括所述化合物的药物组合物。

USPTO Abstract

公开了N－羟基－4－{5－[4－(5－异丙基－2－甲基－1，3－噻唑－4－基)苯氧基]戊氧基}苄脒2甲磺酸盐，其具有优异的生物利用率。也公开了制备所述化合物的方法和包括所述化合物的药物组合物。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN1905871A
Jurisdiction: CN
Classification: —
Expires: 2007-01-31
Drug substance claim: No
Drug product claim: No
Assignee: Dong Wha PharmInd Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.